1 January 2022 in Radiology
Radiomics features determined from chest CT of pure-solid clinical and pathologic stage IA non–small cell lung cancer enabled survival risk stratification. Background Radiomics-based biomarkers enable the prognostication of resected non–small cell lung cancer (NSCLC), but their effectiveness in clinical stage and pathologic stage IA pure-solid tumors ...
1 January 2022 in Radiology
FGfor the Multi-omics Classifier for Pulmonary Nodules (MISSION) Collaborative Group
for the Multi-omics Classifier for Pulmonary Nodules (MISSION) Collaborative Group
+9
The deep learning signature could help accurately predict N2 disease and stratify prognosis in patients with clinical stage I non–small cell lung cancer. Background Preoperative mediastinal staging is crucial for the optimal management of clinical stage I non–small cell lung cancer (NSCLC). Purpose To develop a deep learning signature for N2 metasta...
2 January 2025 in Nature Communications
Diagnosing lung cancer from indeterminate pulmonary nodules (IPLs) remains challenging. In this multi-institutional study involving 2032 participants with IPLs, we integrate the clinical, radiomic with circulating cell-free DNA fragmentomic features in 5-methylcytosine (5mC)-enriched regions to establish a multiomics model (clinic-RadmC) for predicting the malignancy risk of IPLs. The clinic-RadmC yields an area-under-the-curve (AUC) of 0.923 on the external test set, outperforming the single-omics models, and models that only combine clinical features with radiomic, or fragmentomic features in 5mC-enriched regions (p < 0.050 for all). The superiority of the clinic-RadmC maintains well even after adjusting for clinic-radiological variables. Furthermore, the clinic-RadmC-guided strategy could reduce the unnecessary invasive procedures for benign IPLs by 10.9% ~ 35%, and avoid the delayed treatment for lung cancer by 3.1% ~ 38.8%. In summary, our study indicates that the clinic-RadmC provides a more effective and noninvasive tool for optimizing lung cancer diagnoses, thus facilitating the precision interventions.
1 January 2021 in Korean Journal of Radiology
Wang T, et al. Korean J Radiol. 2020 Jul;21:e176. https://doi.org/10.3348/kjr.2020.0454
1 April 2025 in Scientific Data
Diagnosing lung cancer at a curable stage offers the opportunity for a favorable prognosis. The emerging epigenomics analysis on plasma cell-free DNA (cfDNA), including 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) modifications, has acted as a promising approach facilitating the identification of lung cancer. And, integrating 5mC biomarker with chest computed tomography (CT) image features could optimize the diagnosis of lung cancer, exceeding the performance of models built on single feature. However, the clinical applicability of integrated markers might be limited by the potential risk of overfitting due to small sample size. Hence, we prospectively collected peripheral blood sample and the paired chest CT images of 2032 patients with indeterminate pulmonary nodules across 5 centers, and constructed a large-scale, multi-institutional, multiomics database that encompass CT imaging data and plasma cfDNA fragmentomic in 5mC-, 5hmC-enriched regions. To our best knowledge, this dataset is the first radio-epigenomic dataset with the largest sample size, and provides multi-dimensional insights for early diagnosis of lung cancer, facilitating the individuated management for lung cancer.